Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $138, marking a +1.53% move from the previous day.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
by Zacks Equity Research
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company
by Zacks Equity Research
Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
by Kinjel Shah
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA
by Zacks Equity Research
AstraZeneca (AZN) gets the FDA's priority review status for its sNDA seeking label expansion of Farxiga for patients with heart failure with reduced ejection fraction.
3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
by Zacks Equity Research
Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.
Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
by Zacks Equity Research
Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.
Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor
by Zacks Equity Research
Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor
Moving Average Crossover Alert: Eli Lilly and Company
by Zacks Equity Research
Eli Lilly and Company (LLY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
by Zacks Equity Research
Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
Buy These 5 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
A low-risk portfolio can garner healthy returns when some specific parameters are considered.
Top Stock Reports for SAP, AbbVie & Sinopec
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), AbbVie (ABBV) and Sinopec (SNP).
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
by Zacks Equity Research
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.
Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Eli Lilly (LLY) and PNC Financial (PNC).
Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC
by Zacks Equity Research
Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
by Kinjel Shah
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab